VERAXA Biotech Appoints Carl von Halem as Interim CFO
VERAXA Biotech appoints Carl von Halem as interim CFO, succeeding Torsten Bürgermeister. The company is finalizing a permanent CFO to support growth in antibody-based therapeutics.
This CFO transition matters because VERAXA is in a critical growth phase, advancing its pipeline of next-generation antibody-based therapeutics. The appointment of an experienced interim CFO with deep knowledge of the company ensures financial stability during the search for a permanent leader, which is key to maintaining investor confidence and supporting expansion into clinical development.
